Home Merck Receives Complete Response Letter from the U.S. FDA for ZETIA (ezetimibe) and VYTORIN (ezetimibe and simvastatin)
 

Keywords :   


Merck Receives Complete Response Letter from the U.S. FDA for ZETIA (ezetimibe) and VYTORIN (ezetimibe and simvastatin)

2016-02-15 23:30:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck's Supplemental New Drug Applications for ZETIA and VYTORIN for the reduction of the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, or need for revascularization) in patients with coronary heart disease. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Amy Klug, 908-740-1898orTeri Loxam, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: complete response letter receives

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
04.11Tropical Depression Eighteen Graphics
04.11Summary for Tropical Depression Eighteen (AT3/AL182024)
04.11Tropical Depression Eighteen Public Advisory Number 4A
04.11Telekom Srbija renews satellite services contract with SES
04.11Remnants of Patty Graphics
04.11Charter video customers down 294,000 in 3Q 2024
04.11Atlantic Tropical Weather Outlook
04.11Eastern North Pacific Tropical Weather Outlook
More »